BMRN Cash-Secured Put Strategy
BMRN (BioMarin Pharmaceutical Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd.
BMRN (BioMarin Pharmaceutical Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $10.35B, a trailing P/E of 38.36, a beta of 0.23 versus the broader market, a 52-week range of 50.76-66.28, average daily share volume of 2.1M, a public-listing history dating back to 1999, approximately 3K full-time employees. These structural characteristics shape how BMRN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.23 indicates BMRN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 38.36 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a cash-secured put on BMRN?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current BMRN snapshot
As of May 15, 2026, spot at $51.88, ATM IV 36.50%, IV rank 33.73%, expected move 10.46%. The cash-secured put on BMRN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.
Why this cash-secured put structure on BMRN specifically: BMRN IV at 36.50% is mid-range versus its 1-year history, so the credit collected on a BMRN cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 10.46% (roughly $5.43 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BMRN expiries trade a higher absolute premium for lower per-day decay. Position sizing on BMRN should anchor to the underlying notional of $51.88 per share and to the trader's directional view on BMRN stock.
BMRN cash-secured put setup
The BMRN cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BMRN near $51.88, the first option leg uses a $50.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BMRN chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BMRN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $50.00 | $1.90 |
BMRN cash-secured put risk and reward
- Net Premium / Debit
- +$190.00
- Max Profit (per contract)
- $190.00
- Max Loss (per contract)
- -$4,809.00
- Breakeven(s)
- $48.10
- Risk / Reward Ratio
- 0.040
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
BMRN cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on BMRN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$4,809.00 |
| $11.48 | -77.9% | -$3,662.02 |
| $22.95 | -55.8% | -$2,515.03 |
| $34.42 | -33.7% | -$1,368.05 |
| $45.89 | -11.5% | -$221.06 |
| $57.36 | +10.6% | +$190.00 |
| $68.83 | +32.7% | +$190.00 |
| $80.30 | +54.8% | +$190.00 |
| $91.77 | +76.9% | +$190.00 |
| $103.24 | +99.0% | +$190.00 |
When traders use cash-secured put on BMRN
Cash-secured puts on BMRN earn premium while a trader waits to acquire BMRN stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning BMRN.
BMRN thesis for this cash-secured put
The market-implied 1-standard-deviation range for BMRN extends from approximately $46.45 on the downside to $57.31 on the upside. A BMRN cash-secured put lets a trader earn premium while waiting to acquire BMRN at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current BMRN IV rank near 33.73% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on BMRN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, BMRN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BMRN-specific events.
BMRN cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BMRN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BMRN alongside the broader basket even when BMRN-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on BMRN carry tail risk when realized volatility exceeds the implied move; review historical BMRN earnings reactions and macro stress periods before sizing. Always rebuild the position from current BMRN chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on BMRN?
- A cash-secured put on BMRN is the cash-secured put strategy applied to BMRN (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With BMRN stock trading near $51.88, the strikes shown on this page are snapped to the nearest listed BMRN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BMRN cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the BMRN cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 36.50%), the computed maximum profit is $190.00 per contract and the computed maximum loss is -$4,809.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BMRN cash-secured put?
- The breakeven for the BMRN cash-secured put priced on this page is roughly $48.10 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BMRN market-implied 1-standard-deviation expected move is approximately 10.46%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on BMRN?
- Cash-secured puts on BMRN earn premium while a trader waits to acquire BMRN stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning BMRN.
- How does current BMRN implied volatility affect this cash-secured put?
- BMRN ATM IV is at 36.50% with IV rank near 33.73%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.